Filing Details
- Accession Number:
- 0001209191-21-058176
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-30 16:14:44
- Reporting Period:
- 2021-09-28
- Accepted Time:
- 2021-09-30 16:14:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1434316 | Fate Therapeutics Inc | FATE | Biological Products, (No Disgnostic Substances) (2836) | 651311552 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1821530 | Iii J Edward Dulac | C/O Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego CA 92131 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-09-28 | 17,325 | $35.52 | 71,864 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-09-28 | 19,460 | $62.53 | 52,404 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-09-28 | 17,325 | $0.00 | 17,325 | $35.52 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 142,675 | 2030-08-17 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.
- The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.
Billionaire Hedge Funds
